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Abstract 
Background  
To investigate plasma microRNA (miRNA) profiles indicative of hepatotoxicity in 
the setting of lethal acetaminophen (APAP) toxicity in mice.    
Methods  
Using plasma from APAP poisoned mice, either lethally (500 mg/kg) or 
sublethally (150 mg/kg) dosed, we screened commercially available murine 
microRNA libraries (SABiosciences, Qiagen Sciences, MD) to evaluate for 
unique miRNA profiles between these two dosing parameters.  
Results  
We distinguished numerous, unique plasma miRNAs both up- and 
downregulated in lethally compared to sublethally dosed mice.  Of note, many of 
the greatest up- and downregulated miRNAs, included, but were not limited to, 
574-5p, 466g, 466f-3p, 375, 29c, and 148a.  There was a statistically significant 
increase in alanine aminotransferase levels in the lethal compared to sublethal 
APAP dosing groups at the 12 h time point (P < 0.001).  There was 90% mortality 
in the lethally compared to sublethally dosed mice at the 48 h time point (P = 
0.011).  
Conclusion: We identified unique plasma miRNAs both up- and downregulated in 
lethally dosed APAP poisoned mice. 
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CHAPTER I: Introduction 
 
Acetaminophen (APAP) continues to be an important cause of acute liver failure 
in the developed world, second only to infectious etiologies worldwide [1].  It is 
also the most common cause of death due to analgesic ingestion in the United 
States [2].  Numerous emergency department patients in the setting of 
acetaminophen overdose are admitted to hospital for N-acetylcysteine (NAC) 
treatment.  This necessary treatment modality places these patients at risk for 
health-care associated disease.  It also places likely unnecessary additional 
financial strain on an already burdened healthcare system. In addition, the 
estimated U.S. cost of treating intentional acetaminophen overdose is $86.9 
million per year [3].  However, in over 30 years of research it is still unclear how 
the exact mechanism of acetaminophen toxicity occurs [4].   
 
Current literature implicates N-acetyl-para-benzoquinone-imine, or NAPQI, as the 
primary metabolite responsible for hepatotoxicity.  An estimated 90% of APAP is 
metabolized in the liver via either glucuronidation or sulfation.  Another 
approximate 5% is urinated unaltered.  However, approximately 5% of APAP is 
metabolized by the cytochrome P450 2E1 pathway into NAPQI.  In the scenario 
of APAP overdose, the normal route of metabolism becomes overburdened, so 
an overabundance of NAPQI is produced, causing hepatoxicity. Glutathione can 
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rescue this process, and is the reason NAC is used as a treatment modality. 
However, it is presumed only a portion of hepatoxicity occurs via this mechanism.  
Lipid peroxidation via free radical formation, and mitochondrial dysfunction via 
increased permeability of the mitochondrial permeability transition, are also 
postulated as causes of APAP-associated hepatotoxicity [5,6].   
 
Clearly, a better understanding of how APAP specifically causes hepatic toxicity 
from a pathophysiologic perspective still needs to be determined.  In addition, 
standard clinical laboratory testing may not reveal evidence of hepatic injury for 
up to 24 h following APAP ingestion. A considerable proportion of APAP-exposed 
individuals therefore receive unnecessary empiric treatment with an antidote 
before hepatic injury can be ruled out. To overcome this clinical problem, early 
diagnostic indicators of hepatic injury have been sought. 
  
MicroRNA fragments (miRNAs), are short, chemically stable biomolecules, 
noncoding posttranslational regulators that bind to untranslated mRNA 
sequences to produce gene silencing [7-10]. Moreover, each miRNA targets 
several different mRNAs; the same target gene may be regulated by several 
different miRNAs in different biological situations, a process that allows 
enormous complexity and flexibility in their regulatory potential. MicroRNAs have 
been characterized as regulators of protein expression in diverse disease 
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processes, including acute hepatic injury [9,10].   Importantly, miRNAs have 
already been successfully utilized as early biomarkers for esophageal squamous 
cell carcinoma detection in serum [7], identifying Parkinson’s disease onset and 
disease progression [8], and diagnosis of hepatocarcinoma [9,10], demonstrating 
miRNAs as an ideal area of research to determine other early biomarkers for 
disease states, notably APAP-associated hepatotoxicity [11].  In addition, miRNA 
fragments do not require the post-translational modifications necessary in protein 
production; with fewer human miRNAs to evaluate (an estimated 1000 human 
miRNAs compared to approximately 20 000 proteins), there is an improved 
likelihood of identifying unique APAP-associated miRNA profiles [11].    
 
Recent work has also shown the medical utility of miRNA [12,13]. Interestingly, 
literature also supports its association specifically in the setting of acetaminophen 
toxicity.  For instance, Wang et al [11] (2009) showed increased levels of miR-122 
and miR-192 in the plasma of acetaminophen overdosed mice, yet decreased 
levels of these miRNAs in the liver tissue.  In addition, these determined markers 
changed with time and dosing corresponding to histologic liver damage.  Of note, 
these profiles were not evaluated at the lethal APAP dosing of 500 mg/kg, a 
parameter requiring further investigation to specifically compare lethal and 
sublethal miRNA profiles.  Furthermore, additional literature has described 
miRNA involvement in acetaminophen toxicity, as well as the utility of miRNAs as 
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biomarkers useful in the setting of other hepatotoxic disorders, such as hepatitis 
B and C, alcoholic liver disease, non-alcoholic fatty liver disease, and primary 
biliary cirrhosis [14].   
 
However, these miRNAs could be a potential marker for liver toxicity in the 
human patient as well, specifically in the setting of acetaminophen overdose.  
The identification of early plasma markers of acetaminophen toxicity is necessary 
and paramount.  Early identification of acetaminophen toxicity would identify 
those requiring more expeditious treatment, potentially improving morbidity and 
mortality of these individuals.  It would also possibly abrogate the need for patient 
admission, mitigating the resultant financial system burden and iatrogenic risk of 
hospital-acquired infections.   
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CHAPTER II: Methods 
Acetaminophen toxicity 
C57Bl/6 wild-type (WT) mice were purchased from Jackson Laboratory (Bar 
Harbor, ME) and received proper care in agreement with animal protocols 
approved by the Institutional Animal Use and Care Committee of the University of 
Massachusetts Medical School. 
For all experiments, 6-wk-old female C57/BL6 mice, with food deprivation 12 h 
prior to experimentation, were used for intraperitoneal (ip) injections. For lethal 
dosing APAP experiments, 20 C57/BL6 mice were each injected with 
acetaminophen 500 mg/kg  (0.9% normal saline suspension) ip at time zero. For 
the sublethal dosing APAP experiments, 20 C57/BL6 mice were injected with 
acetaminophen 150 mg/kg acetaminophen (0.9% normal saline suspension) ip at 
time zero.  At times 0.5 h, 2 h, 12 h, 24 h, and 48 h, 5 mice per group (both lethal 
and sublethal) were sacrificed via cervical dislocation.  Just prior to sacrifice, 400 
mL of cheek blood was obtained from each mouse.  The whole blood was then 
centrifuged at 14 000 g for 10 min at room temperature.  The plasma was 
removed, aliquoted, and stored at -80°C. After sacrifice, livers were snap frozen 
in liquid nitrogen for protein, stored in RNA stabilization reagent (RNAlater, 
Qiagen, Hilden, Germany) for RNA extraction, or fixed in 10% neutral-buffered 
formalin for histopathologic analysis.  Five mice were injected with saline only ip 
and sacrificed at time 48 h as controls.      
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Hepatoxicity verification 
Alanine aminotransferase (ALT) was quantified by biochemical assay (D-Tek 
Analytical Laboratories Inc, San Diego, CA).  
 
Survival studies 
Ten mice were injected with APAP 500 mg/mL ip and an additional 10 mice were 
injected with APAP 150 mg/mL, all at time zero.   Mice were monitored for 48 h 
and the mortality for each recorded and plotted using Kaplan-Meier survival 
statistics (GraphPad Prism Software, LaJolla, CA).  All mice were housed, 
watered and fed under the same conditions throughout the experimental 
protocol.     
 
Histopathologic analysis 
Sections of formalin-fixed, paraffin-embedded livers after sublethal and lethal 
APAP dosing were stained with hematoxylin and eosin (HE) and assessed for 
inflammatory infiltrate calculated with Microsuite (Olympus Soft Imaging Solution 
GmbH, Munster, Germany) image analysis software in 20 X objective.   
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MicroRNA library screen 
MicroRNA was purified from plasma using the MiRNeasy Mini kit (Qiagen 
Sciences, MD).  The cDNA was prepared using RT2 First Strand cDNA kit 
(SABiosciences, Qiagen Sciences, MD).  The libraries were screened using 
pooled plasma samples from the 12 h time point for each APAP dosing 
parameter using saline injected mice as controls (5 mice/group).  The screening 
libraries utilized were the RT2 miRNA PCR arrays for mouse whole genome, per 
the manufacturer’s protocol (SABiosciences, Qiagen Sciences, MD). Real-time 
quantitative polymerase chain reaction (QPCR) was performed using RT2 qPCR 
SYBR green MasterMix (SABiosciences, Qiagen Sciences, MD) and the iCycler 
iQ Cycler (Bio-Rad Laboratories, Inc, Hercules, CA). 
QPCR data were analyzed using manufacturer software 
(http://pcrdataanalysis.sabiosciences. com/pcr/arrayanalysis.php).  
 
 
 
 
 
 
8 
 
  
CHAPTER III: Laboratory Results  
 
APAP toxicity confirmation: ALT levels and survival 
Numerous plasma miRNAs were both upregulated and downregulated, 
respectively, for the lethally compared to sublethally dosed APAP mice (Figure 
3.1).  Increase in serum levels of alanine aminotransferase (ALT) is a well 
characterized marker of liver injury in the clinical setting as well as in animal 
models.  Hepatoxicity induced by APAP administration in our experiments was 
confirmed utilizing an ALT assay.  An ALT average for the sublethal APAP 
dosing (150 mg/kg) peaked at 883 IU/L and for the lethal APAP dosing (500 
mg/kg) peaked at 7396 IU/L, both at 24 h (Figure 3.2).  There was a statistically 
significant increase in ALT levels in the lethal dosing compared to the sublethal 
dosing groups (642 IU/L compared to 6796 IU/L, respectively) starting at the 12 h 
time point (P < 0.001).  There remained statistically significant increased ALT 
levels for both the sublethal and lethal dosed groups at the 48 h time point 
compared to the 0.5 and 2 h time points (Figure 3.2).  
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Figure 3.1: Plasma microRNA both up- and downregulated in lethally (500 
mg/kg) compared to sublethally (150 mg/kg) dosed APAP mice at the 12 h time 
point. A total of 528 microRNAs were screened using the RT2 miRNA PCR array 
of mouse whole genome, per the manufacturer’s protocol (SABioscience, Qiagen 
Sciences, MD). Quantitiative PCR (QPCR) data were analyzed using 
manufacturer software 
 (http://pcrdataanalysis.sabiosciences.com/ pcr/arrayanalysis.php).  
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Figure 3.2:  Increased hepatoxicity (measured in elevated ALT levels) in lethally 
dosed APAP mice over time. *P < 0.05 between the 2 h, 12 h, 24 h, 48 h time 
points compared to the 0.5 h time point for the 150 mg/kg and 500 mg/kg 
treatment groups, respectively. 
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With administration of a high dose APAP (500 mg/kg), we found that there was 
90% lethality compared to no lethality with the sublethal dosing (150 mg/kg) at 
the 48 h time point as demonstrated by the nonparametric maximum likelihood 
estimate of a Kaplan-Meier survival curve (Figure 3.3). This difference was 
statistically significant at P = 0.011, with ten mice utilized per dosing parameter 
analyzed (Graphpad Prism Software; LaJolla, CA).      
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
  
Figure 3.3: Survival of lethally compared to sublethally dosed APAP mice. 
Kaplan-Meier survival curve over time (h) after sublethal (150 mg/kg) and lethal 
(500 mg/kg) acetaminophen poisoning (P = 0.011).   
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APAP toxicity confirmation: Histology  
For the sublethally dosed mice, the portal and periportal regions appear normal, 
with no signed of centrilobular necrosis or inflammation (Figure 3.4a).  However, 
for the lethally dosed mice, obvious extensive centrilobular necrosis and 
inflammation were present, with distinctively enlarged hepatocytes and highly 
vacuolated cytoplasm.  The lethal dosed liver also demonstrated pyknotic nuclei 
with extensive ballooning vacuolar degeneration (Figure 3.4b).   
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Figure 3.4:  Histopathologic analysis of liver after lethal compared to sublethal 
APAP dosing. Hematoxylin and eosin liver tissue staining at 12 h of (A) 
sublethally (150 mg/kg) acetaminophen poisoned mice, with no signs of 
centrilobular inflammation or necrosis; and (B) lethally (500 mg/kg) APAP 
poisoned mice with extensive centrilobular necrosis, enlarged hepatocytes, and 
highly vacuolated cytoplasm.    
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MicroRNA profile of APAP toxicity 
In an attempt to evaluate plasma miRNAs as potential indicators of APAP-
induced liver damage, we screened plasma of mice after administration of a 
lethal or sublethal dose of APAP. Out of the 528 murine miRNAs analyzed, there 
were more than 40 potential miRNAs that were both greater than 2-fold up- and 
downregulated in the lethal (500 mg/kg) compared to sublethal (150 mg/kg) 
dosing (Table 3.1).   The miRNAs listed were effectively detected suggesting the 
actual fold-change value is as large as the calculated and reported fold-change 
result (SABiosciences, Qiagen Sciences, MD).  The small nucleolar RNA, C/D 
Box 68 (Snord68), was used as the internal control for each library evaluated.      
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Table 3.1: Greatest fold plasma microRNA changes in lethally dosed APAP mice 
 
  
MICRORNA 
FOLD  
INCREASE MICRORNA 
FOLD  
DECREASE 
574-5p 203.7 342-3p 0.0005 
135a* 173.6 195 0.0041 
466g 110.7 375 0.0085 
1196 82.7 29c 0.0134 
466f-3p 71 148a 0.0152 
877 64.4 652 0.0199 
139-3p 59.7 202-5p 0.0317 
686 48.8 200a 0.039 
346 47.5 320 0.0422 
149 34.9 374* 0.0508 
485 34.5 9* 0.0556 
409-3p 30.7 342-5p 0.0629 
202-3p 28.1 192 0.0656 
298 27.4 412 0.0713 
15a 27.1 1 0.0775 
341 26.2 199b 0.0775 
296-3p 24.3 741 0.0902 
466i 22.1 100 0.1145 
1186 21.4 18b 0.1604 
200a 20.5 122     0.2348 
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Finally, we performed an extensive literature search to gather information on the 
known and putative targets of 12 miRNAs that were uniquely changed in the 
plasma after administration of the lethal dose of APAP (Table 3.2).  Interestingly, 
we found 6 out of the top 12 miRNAs with the greatest fold change (both up- and 
downregulated) in the lethally compared to sublethally dosed APAP mice were 
associated with asthma.  The other miRNAs found both highly up- and 
downregulated were found to be associated with hypoxia-inducible factor (HIF)-1 
[15], follicle stimulating hormone [16], type 1 diabetes [17], procollagen Type III [18],  
colon cancer [19], gastric carcinoma [20], and E2F tumor suppression [21] (Table 
3.2).   
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Table 3.2: Lethal APAP-associated plasma microRNAs and potential correlative 
function 
 
 
 
 
 
MicroRNA Function 
574-5p Acute and Chronic Asthma (Garbacki et al 2011); Procollagen Type III 
A1 (Sterling 2010). 
135a Hypoxia-inducible factor (HIF)-1 and NF-kB production (Gonsalves & 
Kalra 2010)  
466g  Acute and Chronic Asthma (Garbacki et al 2011). 
1196 Follicle-Stimulating Hormone regulation (Yao et al 2010). 
466f-3p Acute and Chronic Asthma (Garbacki et al 2011); Procollagen Type III 
A1 (Sterling 2010). 
877 Human Type I Diabetes (Zhou et al 2008) 
139-3p Colon and Rectal Cancer (Slattery et al 2010). 
342-3p HBV Infection and HBV-positive Hepatocarcinoma Biomarker (Li et al 
2010 
195 E2F Tumor Suppressor (Xu et al 2009) 
375 Acute and Chronic Asthma (Garbacki et al 2011); Pyruvate 
Dehydrogenase Kinase Inhibition in Gastric Carcinomas (Tsukamoto et 
al 2010).  
29c Acute and Chronic Asthma (Garbacki et al 2011). 
148a HLA-G and Risk Asthma (Tan et al 2007). 
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Chapter IV: Conclusion 
Lethal dosing of APAP in a murine model is consistent with hepatotoxicity and 
up- and downregulation of a unique pattern of circulating plasma miRNAs, which 
is different from the plasma miRNA profile associated with sublethal APAP 
dosing. These differences may be useful in the future to distinguish lethal and 
sublethal APAP toxicity in humans.  
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Chapter V: Strengths and Limitations 
Strengths: The importance of our work is to establish a novel miRNA nomogram 
that would be used for patients who have taken APAP at an unknown time or 
with chronic ingestions. This would be the first microRNA profile that could 
prognosticate patients who will require (NAC) treatment for hepatoxicity due to 
acetaminophen poisoning. 
Limitations: The specificity of this profile also requires further improvement.  For 
instance, in a recent report miRNA-122 was shown to be increased in the setting 
of APAP toxicity, although this increase was under the detection cut-off of our 
study [11].   Of note, miRNA-122 is also upregulated in hepatitis C settings which, 
by itself, is evidently not specific enough to uniquely identify APAP toxicity [14]. 
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Chapter VI: Discussion 
Our study reveals numerous miRNAs, notably 574-5p, 135a*, 466g, 1196, 466f-
3p, and 877, are upregulated in the setting of lethal compared to sublethal APAP-
associated hepatotoxicity, whereas miRNAs 342-3p, 195, 375, 29c, 148a and 
652 are markedly downregulated (Figure 3.1).  We demonstrate elevated ALT 
levels as well as histologic evidence supporting worsened hepatotoxicity in the 
setting of lethally dosed mice compared to non-lethally dosed mice (Figures 3.2 
and 3.4). With 90% lethality in the lethally dosed mice in relation to no lethality in 
sublethally dosed mice (P = 0.0011), this supports the premise that unique 
plasma miRNA profiles may correlate with non- versus life-threatening APAP 
dosing (Figure 3.3).  The fold-change of a variety of miRNAs in the setting of 
lethally dosed mice compared to sublethal doses is of interest.  Of note, more 
than 40 were both up- and downregulated, with the greatest fold miRNA changes 
reported (Table 3.1).   
 
A literature search to investigate possible functions of the miRNAs both up- and 
downregulated was undertaken (Table 3.2). Intriguingly, many of those most up- 
and downregulated in the lethally compared to sublethally dosed mice, namely 
574-5p, 466g, 466f-3p, 375, 29c, and 148a, have also been implicated in the 
development of asthma [22,23].  For instance, 574-5p may be involved with asthma 
pathogenesis, with decreased miRNA 574-5p in chronic compared to acute 
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asthma in a mouse model sensitized with ovalbumin [23].  In another study, a 
potential relationship between histocompatibility antigen-G, chronic asthma, and 
miRNA 29c was determined [22].  This consequently suggests a pathophysiologic 
relationship between APAP toxicity and asthma [22,23].      
 
Interestingly, prior research has shown an association between APAP use and 
asthma although the exact association is still unclear [24,25].  For instance, an 
adult case control study described a relationship between acetaminophen use 
and asthma [26].  Additional literature revealed an increased risk of wheeze in 
children whose mothers used prenatal APAP [27].  The etiology still remains 
unclear.  However, one theory is that decreased glutathione (due to depletion 
secondary to APAP toxicity) provides the opportunity for unchecked reactive 
oxygen species to promote asthma development [24].  Additional theories include 
increased prostaglandin E2 production secondary to elevated cyclooxgenase-2 
activity in the presence of APAP promoting a T2 allergic response [25]. A third 
cause could be direct lung damage from N-acetyl-p-benzoquinonemine (NAPQI), 
a byproduct of APAP metabolism [28]. Clearly, more information is needed to 
further elucidate the relationship between APAP and risk of asthma.   
 
The previous literature describing the function of the other miRNAs up- and 
downregulated in our study is more varied.  For example, some literature reveals 
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a miRNA 135a association with hypoxia inducible factor 1-alpha (HIF 1-alpha) 
[15].  Interestingly, previous literature has demonstrated HIF 1-alpha induction 
prior to APAP toxicity in the setting of lethal APAP dosing, with toxicity prevented 
by the presence of cyclosporine A, a HIF 1-alpha inhibitor which prevents 
mitochondrial permeability transition and oxidative stress [29]. Additional studies 
have also shown elevation of HIF 1-alpha in the setting of APAP toxicity, with 
increased HIF 1-alpha causing increased glucose transporter-1 expression [30].  
Of note, miRNAs 195 and 342-3p have been shown as involved with 
hepatocytopathology in the setting of tumor suppression in hepatocellular 
carcinoma models [31] and hepatitis B virus (HBV) hepatocarcinoma diagnosis [10], 
respectively.   
 
However, how these miRNAs in total affect hepatotoxicity in the setting of APAP 
poisoning still needs to be elucidated.  Prior studies reveal upregulation of 
plasma mir-122 in the setting of APAP-associated liver toxicity, while our data 
suggest downregulation of plasma mir-122 at the 12 h time point.  This 
discrepancy could be potentially explained by examination of upregulation of mir-
122 at 1, 3 and 24 h time points, not at a 12 h time point in previous literature.  In 
addition, different APAP dosing levels were used in each study (300 mg/kg 
compared to 500 mg/kg), again demonstrating the dynamic nature of miRNA 
regulation across both time and clinical setting [11].  Of note, we found 
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upregulation of plasma mir-298 and mir-370, whereas other researchers found 
downregulation of these miRNAs in the setting of APAP-associated 
hepatotoxicity [32].  Again, this may be due to evaluation at different time points (6 
h compared to 12 h) and differing APAP dosing parameters (1000 mg/kg 
compared to 500 mg/kg) [32].  Together, these results demonstrate the need for 
further identification of additional plasma microRNA profiles at various time points 
and dosing levels.   
 
Our ultimate goal would be to eventually have a miRNA APAP nomogram to be 
used for human patient care, similar to the previous effective Rumack-Matthew 
nomogram [33,34].  The problem with this current nomogram, however, is that it 
relies on knowing when a patient initially ingested APAP.  This is often difficult, if 
patients are poor historians or have ingested mind-altering substances such as 
alcohol at the time of evaluation.   In addition, patients may have been taking 
APAP chronically, not acutely, making use of the Rumack-Matthew nomogram 
pointless.  The importance of our work is to establish a novel miRNA nomogram 
that would be used for patients who have taken APAP at an unknown time or 
with chronic ingestions. In turn, this would avoid investigation of patients who 
have taken it chronically, thus preventing unnecessary treatment and iatrogenic 
ingestions.  Additional studies in this field, with additional time points and dosing 
levels, however, are clearly still necessary.   
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The specificity of this profile also requires further improvement.  For instance, in 
a recent report miRNA-122 was shown to be increased in the setting of APAP 
toxicity, although this increase was under the detection cut-off of our study [11].   
Of note, miRNA-122 is also upregulated in hepatitis C settings which, by itself, is 
evidently not specific enough to uniquely identify APAP toxicity [14].  However, 
with additional future studies and data analysis, this may possible.  This 
approach may also be used as a model to develop profiles for additional disease 
processes, namely non-alcoholic fatty liver disease and hepatocellular 
carcinoma, since microRNA profiles are already being used as early biomarkers 
for numerous pathologic states [9,10].   
 
Together, this may improve the diagnostic accuracy of hepatopathology, namely 
early APAP-induced hepatotoxicity.  In turn, this may allow clinicians to better 
and more rapidly distinguish which patients who have ingested APAP will actually 
mandate therapy.  Subsequently, this may result in decreasing the number of 
patients who receive unnecessary, expensive empiric treatment. 
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